Mei Yu, Shi Min, Zhu Zhenglun, Yuan Hong, Yan Chao, Li Chen, Feng Tienan, Yan Min, Zhang Jun, Zhu Zhenggang
Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Future Oncol. 2022 Jan;18(2):139-148. doi: 10.2217/fon-2021-1020. Epub 2021 Dec 8.
The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive. Peritoneal recurrence is the common and severe relapse pattern. Nanoparticle albumin-bound paclitaxel (Nab-PTX) is safer and more effective than PTX in the peritoneal metastasis. Clinical trial has demonstrated the safety and efficacy of sintilimab in GC. A combination of Nab-PTX, S-1 and sintilimab could be a promising triplet regimen as adjuvant therapy for GC. The aim of this article is to describe the design of this prospective Dragon-VII trial, conducted to evaluate the safety and efficacy of the combination of Nab-PTX, S-1 and sintilimab. NCT04781413.
III期胃癌（GC）的预后并不理想，基于第8版UICC/AJCC TNM分期系统的IIIC期GC的特定化疗方案仍无定论。腹膜复发是常见且严重的复发模式。纳米白蛋白结合型紫杉醇（Nab-PTX）在腹膜转移方面比紫杉醇（PTX）更安全、更有效。临床试验已证明信迪利单抗在GC中的安全性和有效性。Nab-PTX、S-1和信迪利单抗联合使用可能是一种有前景的三联方案，作为GC的辅助治疗。本文旨在描述这项前瞻性的“龙VII”试验的设计，该试验旨在评估Nab-PTX、S-1和信迪利单抗联合使用的安全性和有效性。NCT04781413。
